NasdaqGM - Nasdaq Real Time Price USD

Beta Bionics, Inc. (BBNX)

Compare

11.14

+0.20

+(1.83%)

At close: April 17 at 4:00:01 PM EDT

11.14

0.00

(0.00%)

After hours: April 17 at 4:05:11 PM EDT

Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be a

GlobeNewswire yesterday

BBNX
+1.83%
Beta Bionics to Host Investor Event on June 22, 2025

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8

GlobeNewswire 8 days ago

BBNX
+1.83%
Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

MedTech Dive 20 days ago

BBNX
+1.83%
Beta Bionics Announces Board Appointment of Gerard Michel

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company. “We are excited to welcome Gerard to the Beta Bionics Board,” said Sean Saint, P

GlobeNewswire 21 days ago

BBNX
+1.83%
DCTH
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights & Key Metrics Net sales of $20.4 million, up 145% compared to $8.4 million in the fourth quarter of 2023. Durable Medical Equipment

GlobeNewswire 23 days ago

BBNX
+1.83%
Beta Bionics, Inc. (BBNX): Among Stocks With At Least $10 Million In Insider Spending Recently

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Beta Bionics, Inc. (NASDAQ:BBNX) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, the stock market has […]

Insider Monkey last month

BBNX
+1.83%
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full

GlobeNewswire last month

BBNX
+1.83%
Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Roku (ROKU) to Hold from Underperform with a price target of $100, up from $55, following the Q4 outperformance. Roku’s 25% year-over-year Platform growth was well ahead of its guidance as the company executes on third party integrations and improving fill rates, the firm tells inves

TipRanks last month

SNOW

CMS

SEDG
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectu

GlobeNewswire 2 months ago

BBNX
+1.83%
Beta Bionics raises $204M in IPO

The diabetes tech firm began trading this week and was valued at $966.2 million as of Thursday.

MedTech Dive 2 months ago

BBNX
+1.83%
Beta Bionics raises $204m to kickstart medtech IPO season

Already eclipsing many IPO values in 2024, Beta Bionics hits the Nasdaq boards with a healthy offering.

Medical Device Network 2 months ago

BBNX
+1.83%
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be $204.0 million. In add

GlobeNewswire 2 months ago

BBNX
+1.83%

Performance Overview

Return	BBNX	S&P 500 (^GSPC)
YTD	-49.36%	-10.18%
1-Year	-49.36%	+5.19%
3-Year	-49.36%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Beta Bionics, Inc. (BBNX)

Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

Beta Bionics to Host Investor Event on June 22, 2025

Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Beta Bionics Announces Board Appointment of Gerard Michel

Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025

Beta Bionics, Inc. (BBNX): Among Stocks With At Least $10 Million In Insider Spending Recently

Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Beta Bionics raises $204M in IPO

Beta Bionics raises $204m to kickstart medtech IPO season

Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering

Performance Overview